National and Kapodistrian University of Athens
Διερεύνηση της επιδημίας ηπατίτιδας C και HIV και αξιολόγηση παρεμβάσεων σε κοορτη χρηστών ενδοφλέβιων ναρκωτικών στην Αθήνα
Abstract
dc:descriptionIntroduction: The World Health Organization has set the goal of eliminating hepatitis C and HIV infections as public health problems by 2030. People Who Inject Drugs (PWID) are disproportionately affected by HIV and HCV. In Greece, HCV prevalence is high among PWID entering drug treatment programs, while in 2011 an HIV outbreak occurred among PWID in Athens. Consequently, it is important to monitor trends in HIV and HCV transmission to identify risk factors in order to implement targeted interventions. Aim: The aim of this thesis is: 1) To estimate the size of the PWID population in 2013 and 2018-2020 and, based on this estimate, determine the coverage of harm reduction programs and the burden of hepatitis C and HIV in Athens, Greece, 2) To assess trends in sociodemographic characteristics, injecting practices, access to prevention programs and HIV prevalence in 2018–2020 as compared to 2012–2013, 3) To estimate HIV incidence in 2014–2020, following the 2011 outbreak, and identify risk factors for seroconversion, 4) To investigate trends in hepatitis C transmission in 2014–2020 and associated risk factors, and 5) To estimate all-cause mortality and associated risk factors in 2018–2023.MaterialData were used from two interventions targeting PWID in Athens ("ARISTOTLE", 2012–2013, Ν = 3,320 and "ARISTOTLE HCV-HIV", 2018–2020, Ν = 1,634). These programs aimed to recruit adult PWID residing in the Athens Metropolitan Area with a history of intravenous drug use in the past 12 months. Participants were recruited through Respondent-Driven Sampling (RDS). There were 5 RDS rounds in 2012–2013 and two rounds in 2018–2020. PWID could participate in multiple rounds but only once per round. After obtaining written informed consent, an interview was conducted with a structured questionnaire as well as testing for HCV and HIV. The common design of the programs as well as the use of an anonymous code that allowed unique identification of individuals through their multiple participations, made it possible to create a cohort of PWID with longitudinal data available from the interviews and HIV and HCV testing. For the mortality analysis, data on the survival status of participants and the date of death were obtained from the National Hepatitis C Registry. Methods: The population size of PWID was estimated using the capture-recapture method using as data sources the RDS recruitment rounds in each program. For the 2013 estimate, log-linear models were applied using as sources the four RDS rounds conducted that year. The 2018–2019 estimate was derived from the Lincoln-Petersen estimator, using the two available RDS rounds. HIV incidence was estimated based on seroconversions observed during the programs among initially seronegative PWID with multiple participations. Trends in HCV transmission were estimated using three approaches, utilising both longitudinal seroprevalence data in “new” PWID (injecting duration ≤ 2 years) as well as HCV seroconversion data. Crude all-cause mortality was estimated as well as the standardized mortality ratio (SMR). Risk factors were explored using multiple logistic regression and Cox proportional hazards models, depending on the outcome studied. Results: In 2013, the estimated number of PWID who had injected drugs in the past 12 months was 5,510 (95% CI: 4,958 – 6,063), of whom 4,117 (95% CI: 3,728 – 4,507) were active PWID (injecting in the past 30 days). In 2018–2019, the estimated number of PWID with injecting drug use in the past 12 months was 1,590 (95% CI: 2,324 – 2,658), of whom 1,732 (95% CI: 1,625 – 1,840) were active. The prevalence of intravenous drug use in Athens was estimated at 0.222% (95% CI: 0.200 – 0.245) in 2013 and 0.100% (95% CI: 0.094 – 0.107) in 2018–2019. Using the above population size estimates as the denominator, the coverage of syringe distribution programs in Athens was 103 and 141 syringes per PWID annually in 2013 and 2018–2019, respectively (compared to 216 and 164, based on official size estimates).Among PWID repeatedly tested in 2012–2013 and 2018–2020 in Athens (Ν = 681 individuals), HIV prevalence increased from 14.2% to 22.0%, respectively (55% increase, p Regarding HIV incidence, among 699 initially seronegative PWID with multiple participations, 57 seroconversions were observed in 2014–2020. The estimated incidence was 1.94 (95% CI: 1.50 – 2.52) new cases per 100 person-years. The main risk factor for HIV seroconversion was daily injecting (Hazard Ratio [95% CI] compared to those injecting less often: 2.54 [1.50 – 4.31], p = 0.001).There was a decline in the incidence of primary HCV infection over 2012–2020. Anti-HCV prevalence among new injectors decreased by 25.4% in 2018–2020 compared to 2012–2013 (from 53.6% in 2012–2013 to 40.0% in 2018–2020). HCV incidence, based on observed seroconversions among participants with multiple participations, declined by 78.6% (from 64.6 per 100 person-years in 2012–2013 to 13.8 per 100 person-years in 2018–2020). In multivariable analysis, in 2018–2020 PWID had 68% lower risk of HCV seroconversion compared to 2012–2013 (AHR [95% CI]: 0.32 [0.13 – 0.77], p = 0.011) and there was a marginally statistically significant difference between Greek and PWID with other country of origin (AHR [95% CI] for foreigners versus Greek: 2.23 [0.92 – 5.43], p = 0.078).During 2018–2023, crude all-cause mortality was estimated at 3.16 deaths per 100 person-years and showed an increasing trend. After adjustment for age and sex, mortality among PWID was almost 14.1 times higher compared to the general Greek population. Older age, Greek origin, daily injection, homelessness, and HIV infection were independently associated with all-cause mortality. Conclusions: In 2013 and 2018–2019, the estimated number of active PWID was 2.1 and 1.2 times higher compared to official estimates based on drug treatment data. Based on these new estimates, syringe coverage in Athens during these periods was considerably lower than the target of 200-300 syringes per PWID annually. The above highlights the need to include as many data sources as possible when applying the capture-recapture methodology to obtain reliable population size estimates of PWID. HIV incidence in 2014-2020 remained stable, at moderate levels, similar to those achieved in the second half of 2013. Despite the significant decline in anti-HCV prevalence among “new” injectors and in HCV incidence over 2012–2020, the levels of HCV transmission among PWID in Athens remain high. Mortality among PWID in Athens is higher compared to estimates from other PWID studies and the general population of Greece. Given that overdose is a leading cause of death among PWID, preventive programs such as take-home naloxone distribution are warranted. The high levels of HIV and HCV transmission highlight an important public health problem. To achieve the elimination goals in this population, systematic implementation of high coverage harm reduction programs, frequent testing of high-risk PWID - primarily active injectors and PWID injecting daily, not linked to drug treatment programs, homeless - and facilitated access to treatment are required.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Roussos, Sotirios
- Ρούσσος, Σωτήριος
Subjects
dc:subject × 24- Άνθρωποι με χρήση ενδοφλέβιων ναρκωτικών (ΑΧΕΝ)
- Επιδημία
- Επιπολασμός
- Επίπτωση
- Θνησιμότητα
- Ηπατίτιδα C, Ιός (HCV)
- HIV λοίμωξη
- Αθήνα
- People who inject drugs (PWID)
- Outbreak
- Prevalence
- Incidence
- Mortality
- HCV
- HIV
- Athens
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιδημιολογία
- Λοιμώδη νοσήματα
- Health Sciences
- Medical and Health Sciences
- Epidemiology
- Infectious Diseases
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54960